Country: দক্ষিণ আফ্রিকা
ভাষা: ইংরেজি
সূত্র: South African Health Products Regulatory Authority (SAHPRA)
Aspen-p
ASPEN DIDANOSINE 150 mg Tablet ASPEN DIDANOSINE 100 mg Tablet ASPEN DIDANOSINE 50 mg Tablet ASPEN DIDANOSINE 25 mg Tablet SCHEDULING STATUS: S4 PROPRIETARY NAME (and dosage form): ASPEN DIDANOSINE 150 mg Tablet ASPEN DIDANOSINE 100 mg Tablet ASPEN DIDANOSINE 50 mg Tablet ASPEN DIDANOSINE 25 mg Tablet COMPOSITION: Each ASPEN DIDANOSINE 150 mg TABLET contains Didanosine 150 mg. Each ASPEN DIDANOSINE 100 mg TABLET contains Didanosine 100 mg. Each ASPEN DIDANOSINE 50 mg TABLET contains Didanosine 50 mg. Each ASPEN DIDANOSINE 25 mg TABLET contains Didanosine 25 mg. PHENYLKETONURICS: CONTAINS ASPARTAME (a phenylalanine) PHARMACOLOGICAL CLASSIFICATION: A.20.2.8 Antiviral agents PHARMACOLOGICAL ACTION: Didanosine (2’, 3’-dideoxyinosine) is a purine nucleoside analog active against HIV-1 and HIV2 in vitro. Following intracellular diffusion, didanosine is metabolised initially by 5’-nucleotidase and further by other cellular enzymes to its active derivative, 2’, 3’-dideoxyadenosine triphosphate (ddATP). DdATP functions as a competitive inhibitor of viral reverse transcriptase with respect to deoxyadenosine triphosphate and as a chain terminator of viral DNA synthesis. PHARMACOKINETICS: Adults: Didanosine is rapidly degraded at an acidic pH. The bioavailability of didanosine is significantly reduced by the presence of food. Therefore Aspen Didanosine should be administered at least 30 minutes before a meal or in the fasting state. Although patients exhibit significant variability, Cmax and AUC values increase in proportion to the dose. The steady state volume of distribution after IV administration averages 54 L. The concentration in the cerebrospinal fluid averages 21% of the simultaneous plasma concentration 1 hour after an intravenous dose. In patients with norm সম্পূর্ণ নথি পড়ুন